Overview
- Reviews innovative methods, tools and examples of rational drug development strategies, particularly for novel oncological agents
- Includes supplementary material: sn.pub/extras
Part of the book series: Ernst Schering Foundation Symposium Proceedings (SCHERING FOUND, volume 59)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (16 papers)
-
Front Matter
-
Back Matter
Keywords
About this book
Optimal dose individualization has become more important in improving clinical efficacy and safety, given the variability in drug response, e.g., due to concurrent illnesses or co-medications. Therefore, the role of optimal dose finding in early clinical drug development so as to maximize successful clinical use is emphasized. The continued use of biomarkers – based on the (known) pharmacology of the drug and/or biology of the underlying disease – along with exposure–response evaluation throughout all phases of drug development can quantitatively integrate clinical pharmacology knowledge, provide early proof of concept, and help in rational dose selection and rational drug product labeling for clinical use.
Editors and Affiliations
Bibliographic Information
Book Title: Appropriate Dose Selection - How to Optimize Clinical Drug Development
Editors: J. Venitz, W. Sittner
Series Title: Ernst Schering Foundation Symposium Proceedings
DOI: https://doi.org/10.1007/978-3-540-49529-1
Publisher: Springer Berlin, Heidelberg
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer-Verlag Berlin Heidelberg 2007
Hardcover ISBN: 978-3-540-27867-2Published: 19 October 2006
Softcover ISBN: 978-3-642-42176-1Published: 28 November 2014
eBook ISBN: 978-3-540-49529-1Published: 06 March 2007
Series ISSN: 0947-6075
Edition Number: 1
Number of Pages: XVI, 216
Topics: Pharmacology/Toxicology, Medicine/Public Health, general, Biochemistry, general